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Gene expression proﬁleAbstract Gastric cancer (GC) is one of the most frequent malignant tumors. In order to
systematically characterize the cellular and molecular mechanisms of intestinal GC development,
in this study, we used 22 K oligonucleotide microarrays and bioinformatics analysis to evaluate
the gene expression proﬁles of GC in 45 tissue samples, including 20 intestinal GC tissue samples,nces and
Zang S et al / Gene Expression Proﬁling of Intestinal Gastric Cancer 27720 normal appearing tissues (NATs) adjacent to tumors and 5 noncancerous gastric mucosa tissue
samples. These proﬁles allowed us to explore the transcriptional characteristics of GC and deter-
mine the change patterns in gene expression that may be of clinical signiﬁcance. 1519 and 1255 dif-
ferentially-expressed genes (DEGs) were identiﬁed in intestinal GC tissues and NATs, respectively,
as determined by Bayesian analysis (P< 0.001). These genes were associated with diverse functions
such as mucosa secretion, metabolism, proliferation, signaling and development, which occur at dif-
ferent stages of GC development.Introduction
Gastric cancer (GC) is one of the most common malignant
tumors. It is estimated that one million new cases are reported
worldwide each year [1], with around two-thirds of GC occur-
ring in developing countries. Although considerable effort has
been directed toward the development of surgical and chemo-
therapeutic interventions, the prognosis for patients with
advanced stages of GC remains poor. Thus, a major challenge
toward assessing and, perhaps, improving the clinical outcome
of the treatment of GC patients is to better understand the
molecular basis of the disease and its development, i.e., the
key changes of gene expression patterns in gastric tumorigen-
esis. The relationship between speciﬁc gene expression patterns
and certain properties of GC have been previously described,
including resistance to chemotherapeutics [2], metastatic
potential [3,4] and prognosis following a particular treatment
[5,6]. However, to understand the underlying mechanisms of
gastric tumorigenesis, it is essential to characterize the
biological processes that initiate the development of GC and
its subsequent progression, especially, to document the gene
expression pattern from a high-risk population of GC. In this
study, we have characterized the transcriptional proﬁles of GC
in Chinese patients by using 22 K oligonucleotide microarrays
and have identiﬁed differentially-expressed genes (DEGs)
within GC, GC adjacent and normal tissues. These expression
patterns were further examined by identifying molecular path-
ways associated with GC development.Results
Genes differentially expressed between intestinal GC and normal
gastric mucosa tissues
To understand the expression proﬁle of intestinal GC, we
collected 45 tissue samples, including 20 intestinal GC tissue
samples, 20 normal appearing tissues (NATs) adjacent to
tumors and ﬁve noncancerous gastric mucosa tissue samples,
and performed microarray study to evaluate the gene expres-
sion proﬁle. After normalization, a Bayesian analysis of gene
expression level (BAGEL) was used to characterize differential
gene expression between intestinal GC tissue samples and non-
cancerous gastric mucosa tissue samples with a signiﬁcance
cutoff of P< 0.001. A total of 1519 genes were recognized
to be differentially expressed in intestinal GC when compared
to normal gastric mucosa tissue (Figure S1). These included
593 upregulated and 926 downregulated genes. Hierarchical
clustering of these DEGs demonstrated a dramatic variation
in gene expression in tumors compared with normal gastric
mucosa tissue. Tables S1 and S2 list P value, fold change
and name of each DEG. Among these DEGs, 11 and 29 geneswere upregulated and downregulated with fold change >10,
respectively. The annotation analysis from GoMiner indicated
that some of these genes were related with gastric physiological
function, such as ATPase, somatostatin and gastrin.Prediction of tumor-speciﬁc biological characteristics associated
with DEGs in intestinal GC
Based on gene expression proﬁle of GC, we were able to
identify tumor-speciﬁc biological characteristics that correlate
with DEGs. Using currently available chip annotation tools,
including DAVID, SOURCE and the high-throughput
GoMiner, we obtained the functional description, classiﬁca-
tion and location of the DEGs. Annotation results showed
that these 1183 DEGs were known genes associated with a
diverse set of biological pathways and functions in both cell-
and organ-speciﬁc physiological processes (Table 1).Prediction of tumor-speciﬁc pathways associated with gene
expression proﬁling in intestinal GC
Signal transduction pathways associated with gene expression
changes were analyzed and deﬁned using the bioresource for
array genes (BioRag, www.biorag.org). A total of 143 signal
transduction pathways contained genes that were differentially
expressed. Among them, 14 pathways showed altered expres-
sion of at least three up-regulated genes within each (Table 2).
These pathways include the MAPK signaling pathway, inﬂam-
matory response pathway, TGF-b pathway and pathways
associated with extracellular matrix synthesis and regulation
of gluconeogenesis. Six pathways were changed with at least
three downregulated genes (Table 3).Genes differentially expressed between NATs and normal gastric
mucosa tissues
Although NATs appear morphologically normal, Figure S2
demonstrated that the gene expression pattern of these tissues
is very different from that of normal gastric mucosa tissues. A
total of 1255 DEGs, including 561 upregulated and 694 down-
regulated genes, were identiﬁed with a P < 0.001 signiﬁcance
cutoff. The detailed information describing the upregulated
and downregulated genes is presented in Table S3 and
Table S4.Comparison of gene expression patterns between GC tumors and
NATs
The number of DEGs in GC and NATs is shown and clustered
according to different fold changes in Figure 1. Our data above
Table 3 List of signaling pathways affected with at least three downregulated genes
Pathway Number Gene
Electron transport chain 11 COX17, NDUFC2, COX5B, GPRC5B, COX7A2L, PHKB, NDUFB8, NDUFA8,
NDUFA10, ATP5O, ADRA2A
Glycolysis and gluconeogenesis 10 GSN, RHOA, FGFR2, ALDOC, FBP1, FBP2, SLC9A1, HK1, CFL1, PIP5K1B
Rho cell motility signaling pathway 5 GSN, RHOA, CFL1, PIP5K1B, ARPC2
HIV-I Nef: negative eﬀector of Fas and TNF 4 GSN, CASP7, CASP6, PRKCD
Y branching of actin ﬁlaments 3 PIR, ARPC2, WASL
Role of PI3 K subunit p85 in regulation of actin
organization and cell migration
3 RHOA, ARPC2, WASL
Table 2 List of signaling pathways affected with at least three upregulated genes
Pathway Number Genes
MAPK signaling pathway 12 STK3, DUSP6, RASA2, MYC, NR4A1, GADD45B, CDC25B,
FOS, PDGFRB, PLA2G2A, DUSP1, ARAF1
Inﬂammatory response pathway 6 COL1A2, LAMC1, FN1, COL3A1, COL1A1, LAMB1
Complement and coagulation cascades 7 DAF, PLAU, TFPI, SERPINE1, C1R, PROS1, C1S
Role of EGF receptor transactivation
by GPCRs in cardiac hypertrophy
5 ADAM12, FOS, MYC, EDNRA, EDN1
Glycolysis and gluconeogenesis 3 TGIF, SERPINE1, THBS1
Inhibition of matrix metalloproteinases 4 TIMP3, TIMP2, TIMP1, MMP2
TGF-b signaling pathway 4 INHBB, MYC, FST, THBS1
Wnt signaling 5 WNT16, PLAU, SFRP4, MYC, SFRP2
Toll-like receptor signaling pathway 4 CXCL9, IL8, CCL3, FOS
Prostaglandin and leukotriene metabolism 4 PTGS2, PTGIS, PLA2G2A
Rac 1 cell motility signaling pathway 4 CHN1, NCF2, MYLK, TRIO
Acute myocardial infarction 3 COL4A1, PROS1, TFPI
Cell cycle 3 GADD45B, E2F3, CDC25B
Mechanism of gene regulation by peroxisome
proliferators via PPAR a
3 PTGS2, MYC, DUSP1
Table 1 Functional alterations due to DEGs in intestinal GC samples (FDR < 0.05)
Level Functional category Change status FDR Number of DEGs
Cell level Cell motility › 0.045192 52
Cell proliferation › 0.005 73
Cell communication › <0.0001 73
Glycoprotein metabolism ﬂ <0.0001 27
Cellular lipid metabolism ﬂ 0.011739 90
Cellular carbohydrate metabolism ﬂ 0.012273 41
Protein amino acid glycosylation ﬂ <0.0001 8
Organ level Development › 0.001429 173
Morphogenesis › 0.001667 45
Immune response › 0.001333 44
Neurophysiological process › 0.025385 34
Digestion ﬂ <0.0001 15
Note: False discovery rate (FDR) is used to assess the signiﬁcance of a particular category in GoMiner. DEG, differentially-expressed gene.
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tumors (vs. normal) and NATs (vs. normal), respectively.
Among these DEGs, 550 genes were shared between GC
tumors (vs. normal) and NATs (vs. normal), including 169
upregulated and 381 downregulated genes (Figure S3,
Figure 2). The annotation results showed that these genes are
involved in a number of different pathways and processes,
such as amino acid glycosylation, biopolymer glycosylation
and glycoprotein biosynthesis. Among the different genes
between NATs and GC, nine genes were reversely expressedin two groups (Table 4), including ATP4B, ATP4A, CCKBR,
KCNJ16, SIAT1, DUOX1, WDR37 and APOBEC2.Characterization of the altered expression of genes associated
with mucosal barrier function and secretion of GC tissues and
NATs
Disruption of the mucosal barrier is associated with some
primary gastric disorders [7]. Therefore, we analyzed the
Figure 1 Number of DEGs in GC samples and NAT under various
FC criteria
More DEGs were detected in GC than NAT, when compared to
the normal tissues. DEG, differentially-expressed gene; NAT,
normal appearing tissue adjacent to tumor; FC, fold change.
GC  vs. normal                                                     NAT vs. normal  
424                169            392          
545                381               313 
Upregulated
Downregulated
Figure 2 Distribution of DGEs between NAT and intestinal GC
samples
Number of DEGs in NAT and intestinal GC samples. The
overlapping regions show the shared numbers of DEGs in two
tissues. Blue represents GC tissue and red represents NAT.
Table 4 Opposite pattern of gene expression in NAT and GC samples
Accession Symbol GC NAT Protein name
Expression FC P value Expression FC P value
NM_000705 ATP4B Down 31.47 <0.0001 Up 9.38 <0.0001 ATPase, H+/K+exchanging, beta polypeptide
NM_000704 ATP4A Down 15.96 <0.0001 Up 3.05 <0.0001 ATPase, H+/K+exchanging, alpha polypeptide
NM_000731 CCKBR Down 4.49 <0.0001 Up 2.34 <0.0001 Cholecystokinin B receptor
NM_018658 KCNJ16 Down 3.79 <0.0001 Up 4.49 <0.0001 Potassium inwardly-rectifying channel,
subfamily J, member 16
NM_003032 SIAT1 Down 2.86 <0.0001 Up 5.04 <0.0001 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1
NM_017434 DUOX1 Down 2.34 <0.0001 Up 3.2 <0.0001 Dual oxidase 1
NM_014023 WDR37 Down 1.59 <0.0001 Up 2.23 <0.0001 WD repeat domain 37
NM_006789 APOBEC2 Down 1.47 0.0002 Up 3.24 <0.0001 Apolipoprotein B mRNA editing enzyme,
catalytic polypeptide-like 2
Note: Fold changes (FC) are the absolute value of log2 (GC expression/normal expression) or the log2 (NAT expression/normal expression).
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identiﬁed 18 candidates that were differentially expressed,
including 6 genes that were downregulated in NATs (Table 5)
and 12 genes that were dramatically downregulated in GC tis-
sues (Table 6). This result indicated that both NATs and GC
tissues lose some normal physiological functions, with thealteration in the expression of barrier function-related genes
being more frequent in NATs, followed by the alteration in
the expression of secretion-related genes in the GC tissues.
A tumorigenic model based on selected genes and their networks
in GC
In this study, we integrated the inference of gene expression
proﬁle with the known clinical features of stomach cancer over
time to predict cancer progression (Figure 3). The information
we could infer from the gene expression proﬁles in this study is
listed below. (1) Characterization of altered gene expression of
genes involved in barrier and secretion of GC tumors and
NATs. (2) Cellular metabolism and cell function alterations
due to DEGs. (3) The changes of signal transduction pathways
due to DEGs. The known clinical features of stomach cancer
over time are listed below. (1) Before cancer develops,
pre-cancerous changes often occur in the inner lining (mucosa)
of the stomach [8,9]. These early changes rarely cause symp-
toms and therefore often go undetected. (2) Stomach cancers
tend to develop slowly over time. (3) Stomach cancers can
spread (metastasize) in different ways. They can grow through
the wall of the stomach and invade nearby organs. Finally,
abnormalities that are related to cell proliferation, tissue
architecture and remodeling, as well as differentiation and
development emerge as cancer progresses.Discussion
A key goal of cancer studies is to systematically characterize
the cellular and molecular mechanisms involved in disease
progression, and consequently, to identify potential biomark-
ers for predicting the prognosis of patients [10]. Genomic
and proteomic studies on GCs have predominantly been
reported from the Western countries and Japan [11–13]; only
a few studies on GC have been reported from China [14,15].
Molecular pathology of GC may vary among populations,
which is likely due to differential exposure to disease risk
factors including diet, Helicobacter pylori variants, smoking,
alcohol consumption and other underlying medical conditions.
In this study, our objective was to establish a comprehensive
gene expression proﬁle for GC in Chinese patients, a known
high-risk population, and to investigate the mechanisms
underlying GC carcinogenesis.
Table 5 DEGs involved in normal biological functions of gastric mucosa in NAT
Gene description Accession Symbol Fold change P value
Intrinsic barrier
Occludin NM_002538 OCLN 1.812 0.0001
Catenin NM_001903 CTNNA1 1.999 <0.0001
Extrinsic barrier
Mucin 7, salivary L13283 MUC7 1.687 0.0001
Defensin, beta 1 NM_005218 DEFB1 5.568 <0.0001
Gastric secretion-related genes
Gastrin NM_000805 GAS 9.916 <0.0001
Carbonic anhydrase II NM_000067 CA2 2.424 <0.0001
Note: Fold changes are the absolute value of log2 (NAT expression/normal expression).
Table 6 DEGs involved in normal biological functions of gastric mucosa in intestinal GC samples
Gene description Accession Symbol Fold change P value
Intrinsic barrier
Occludin NM_002538 OCLN 2.63301 <0.0001
Claudin 18 NM_016369 CLDN18 4.96291 <0.0001
Claudin 23 BC016047 CLDN23 2.88944 <0.0001
Catenin NM_001903 CTNNA1 2.00327 <0.0001
Extrinsic barrier
Mucin 1, transmembrane J05582 MUC1 2.27442 <0.0001
Mucin 7, salivary L13283 MUC7 1.57293 <0.0001
Trefoil factor 2 NM_005423 TFF2 9.65021 <0.0001
Defensin, beta 1 NM_005218 DEFB1 7.9556 <0.0001
Gastric secretion-related genes
Carbonic anhydrase II NM_000067 CA2 13.20503 <0.0001
Progastricsin NM_002630 PGC 6.94681 <0.0001
Gastrin NM_000805 GAS 13.5022 <0.0001
Cholecystokinin B receptor NM_000731 CCKBR 4.49452 <0.0001
Note: Fold changes are the absolute value of log2 (GC expression/normal expression).
Figure 3 A tumorigenic model for GC development and progression
A tumorigenic model depicts GC development and progression. Dysfunction of the mucosal barrier appears to occur as an early event.
Subsequently, metabolic abnormalities appear, following excessive DNA replication. Finally, abnormalities related to cell proliferation,
tissue architecture and remodeling, as well as differentiation and development emerge as the tumor progresses. The vertical arrows mean
accumulation of gene alterations. Each functional category was shown as a color code.
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array analysis on 20 intestinal GC tissue samples and 20 NATs
adjacent to tumors of intestinal GC in comparison with the
ﬁve normal samples, respectively. Gene expression proﬁles
were generated for samples from intestinal GC, NATs and
normal tissues. Following a systemic analysis, we integrated
the gene expression patterns, functional annotations and
clinical characteristics that were associated with GC. Further-
more, we identiﬁed the expression proﬁles of genes involved in
functional pathways associated with gastric mucosal barrier
function and gastric secretion. Altogether, our data provided
insights into gastric carcinogenesis and proposed new leads
toward the discovery of possible biomarkers for the early diag-
nosis of GC.
Our study has generated comprehensive gene expression
proﬁles of GC. Our data showed that a number of DEGs
may be important in the development of intestinal GC. We
found that nine genes were reversely expressed between NATs
and GC, including ATP4B, ATP4A, CCKBR, KCNJ16,
SIAT1, DUOX1, WDR37 and APOBEC2. These genes were
involved in oxidative phosphorylation, N-glycan biosynthesis,
atrazine degradation and glycan structures biosynthesis. This
result provides some new clues to explore the mechanisms of
GC development.
To our knowledge, this report, for the ﬁrst time, compre-
hensively described the alterations in the gene expression pat-
terns of NATs and intestinal GC tumors compared to normal
tissues. DEGs shared by GC tumors (vs. normal tissues) and
NATs (vs. normal tissues) might be essential for tumorigenesis.
These differences may reﬂect the signiﬁcant roles of tissue
architecture and remodeling that occurs during GC develop-
ment. Similarly, we have also identiﬁed a group of DEGs,
including EGR1, CYR61 and ADAMTS1, which are differen-
tially expressed between intestinal metaplasia/dysplasia and
normal mucosa [16]. However, the dramatic changes in extra-
cellular matrix and cellular communication pathways that
were noticed in tumor tissues were rarely observed in NATs.
These data suggest that tissue remodeling may be essential
for tumor development, possibly by maintaining the environ-
ment around the tumor cells and supporting cellular survival.
Importantly, we have also identiﬁed distinct gene expres-
sion patterns related to abnormal physiological functions of
the gastric mucosa, including gastric barrier and secretion.
The gastrointestinal barrier has two components, the intrinsic
and extrinsic barriers [17]. The intrinsic barrier is composed of
epithelial cells lining the digestive tract and the tight junctions
that tie them together. The extrinsic barrier comprises secre-
tions and other factors that are not physically part of the epi-
thelium, but affect the epithelial cells and maintain their
barrier function, such as mucus, trefoil proteins and defensins.
Our data show that normal gastric physiological functions are
lost in both the gastric tumor and NATs. In NATs, genes
related to barrier function are almost all downregulated; while
in the GC samples, mainly the secretion-related genes are
downregulated. Alterations in gene expression in NATs indi-
cate that lesions of the gastric mucosal barrier might aggravate
the mucosal damage insulted by various cancer-related risk
factors.
A tumorigenic model was created to depict GC develop-
ment and progression. At the initial stage, dysfunction of the
mucosal barrier appears to occur as an early event. Then,
metabolic abnormalities occur following excessive DNAreplication, which would result in genomic instabilities.
Finally, abnormalities that are related to cell proliferation, as
well as tissue architecture, remodeling, differentiation and
development emerge as the cancer progresses. In future study,
we will collect pre-cancer and gastric cancer samples for gene
expression analysis to examine this model.
Materials and methods
Specimens and RNA isolation
All specimens were obtained with the written consent of the
patients and were histologically graded, according to the
guidelines put forth by the Union for International Cancer
Control (UICC). The study was approved by the Committee
on Human Studies, School of Oncology, Peking University.
Specimens of GC (veriﬁed by histopathology) were obtained
from the Tissue Bank of Peking University, School of
Oncology. We selected 20 intestinal GC tissue samples, 20
tumor-adjacent NAT samples, and 5 normal gastric mucosa
tissue samples for microarray experiments. RNA was extracted
with TRIzol reagent (Life Technologies, Inc., Gaithersburg,
MD) and was further puriﬁed using a Nucleospin RNA
Clean-up Kit (Clontech Laboratories, Inc., Mountain View,
CA), according to the manufacturer’s instructions. The RNA
quality was assessed by formaldehyde agarose gel electropho-
resis and was quantitated spectrophotometrically.
Microarray fabrication
The human genome oligonucleotide microarray was prepared
in CapitalBio Corporation (Beijing, China). A Human Gen-
ome Oligo Set Version 2.1, consisting of approximately
22,000 human genes, was purchased from Qiagen Operon
(Germantown, MD, USA). As external controls, an additional
eight oligonucleotides that recognize yeast intergenic sequences
were included together with the internal controls provided by
the manufacturer. All nucleotides were dissolved in 50%
DMSO to obtain a ﬁnal concentration of 40 lM and were
printed on in-house manufactured aminosilanated glass slides.
Arrays were fabricated using a SmartArrayTM microarrayer
(CapitalBio Corp., Beijing, China). After printing, the slides
were baked at 80 C for 1 h and stored dry at room tempera-
ture until use. Prior to hybridization, the slides were rehy-
drated at 65 C for 10 s, snap dried on a 100 C heating
block for 5 s, and UV cross-linked at 250 mJ/cm2. Unbound
oligonucleotides were washed off with 0.5% SDS for 15 min
at room temperature, and SDS was removed by dipping the
slides in anhydrous ethanol for 30 s. The slides were spin-dried
at 1000 rpm for 2 min.
Probe labeling, hybridization, image analysis and normalization
The microarray experimental procedures were described in the
previous published paper [18]. DNA in hybridization solution
was denatured at 95 C for 3 min prior to loading on to the
microarray. The array was hybridized at 42 C overnight.
After hybridization, microarrays were rinsed consecutively
with two types of washing solutions (with one solution con-
taining 0.2% SDS and 2 · SSC at 42 C for 5 min and with
another solution containing 0.2% SSC at room temperature
282 Genomics Proteomics Bioinformatics 12 (2014) 276–283for 5 min). Arrays were scanned with a confocal LuxScan
scanner (CapitalBio Corporation) and resulting images were
analyzed with Spot Data software (CapitalBio Corporation),
using a space- and intensity-dependent normalization of ﬂuo-
rescence, based on a locally-weighted scatterplot smoothing
(LOWESS) algorithm [19].
Statistics, annotation, relative gene expression and biological
pathway analyses
Relative gene expression levels were determined using a Bayes-
ian method (Bayesian analysis of gene expression levels,
BAGEL) [20] from the normalized ratio data. This approach
estimates the relative expression level for each gene based on
the ﬂuorescence ratio of Cy5/Cy3 ﬂuorophores. For all com-
parisons, unless otherwise stated, difference was considered
to be signiﬁcant at P< 0.001. DEGs were identiﬁed with
non-overlapping 95% conﬁdence intervals from the Bayesian
analysis. The fold change criteria were identiﬁed as mentioned
in our previous report [21]. BAGEL has the advantage of
detecting small yet statistically signiﬁcant differences, which
might be of biological signiﬁcance. Hierarchical clustering of
DEGs, as determined by BAGEL, was performed with Cluster
[22,23] and Genesis [23], using the average linkage algorithm.
Gene annotation in terms of the associated pathways was per-
formed using DAVID [24], SOURCE [25] and GoMiner [26].
Signal transduction pathways were analyzed by BioRag [27].
Biological signature analysis was performed to correlate gene
expression patterns with clinical characteristics, including
age, gender, pathology, differentiation, lymph node metastasis
and survival time, which were commonly used to predict clin-
ical outcomes and prognosis.
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